Parallax Volatility Advisers, L.P. Cassava Sciences Inc Call Options Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $331,136 - $503,868	19,900 Added 19900.0%	20,000 $332,000
Q2 2023 Aug 14, 2023	SELL	$21.59 - $27.88 $1.08 Million - $1.39 Million	-50,000 Reduced 99.8%	100 $2,000
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $1.58 Million - $2.45 Million	-67,300 Reduced 57.33%	50,100 $1.21 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $2.51 Million - $3.98 Million	90,200 Added 331.62%	117,400 $3.47 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $342,929 - $1.07 Million	21,000 Added 338.71%	27,200 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$17.22 - $38.47 $106,764 - $238,514	6,200 New	6,200 $174,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $459,660 - $748,005	-14,100 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $2.17 Million - $5.37 Million	-59,100 Reduced 80.74%	14,100 $616,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $3.3 Million - $10.7 Million	-78,900 Reduced 51.87%	73,200 $4.54 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $4.89 Million - $13.6 Million	152,100 New	152,100 $13 Million

191

13.7M

2.97M

6.55M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $95.4M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.